Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX-002 in Adults With Bipolar Depression
NCT06869187Phase 2Active, not recruiting
- Sponsor
- Autobahn Therapeutics
- Start
- Mar 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of elunetirom in bipolar disorder (BD) (2 arms), sponsored by Autobahn Therapeutics. Primary endpoint: 17-item Hamilton Rating Scale for Depression at 6 weeks. Started Mar 2025; status: active, not recruiting.
02
Drugs
elunetirom
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT06869187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06869187.